Page 1

Q2 Half - Year Financial Report 2021 Bayer : Strong growth , guidance upgrade BAYER BAYER // Group sales at € 10.9 billion ( Fx & p adj . + 12.9 % ) - double - digit percentage growth ( Fx & p adj . ) at all divisions // EBITDA before special items at € 2.6 billion ( -10.6 % ) , burdened by currency effects of € 0.2 billion // Crop Science posts strong sales growth , earnings impacted by higher costs and currency effects // Pharmaceuticals reports significant recovery after COVID - 19 effects in prior year // Consumer Health continues growth momentum // Core earnings per share € 1.61 ( + 1.3 % ) // Net income at minus € 2.3 billion ; additional € 3.5 billion in provisions established for glyphosate litigations // Strong free cash flow of € 1.2 billion // Full - year guidance upgraded // Good pipeline news : Kerendia ™ gains U.S. approval ; acquisition of Vividion Therapeutics agreed ; start of first clinical study for Parkinson's cell therapy treatment Science for a better life